8-K current report · filed Aug 11, 2026

Sanara MedTech Inc. (SMTI) 8-K Current Report: August 11, 2026

Item EX-99.1Item 2.02SMTI overview

Short answer

Sanara MedTech Inc. (SMTI) filed an 8-K current report with the SEC on August 11, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Fiscal quarter ended June 30, 2026 results announced by Sanara MedTech.

Sanara MedTech Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Fiscal quarter ended June 30, 2026 results announced by Sanara MedTech
  • Press release contains the financial figures and operating commentary in Exhibit 99.1

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue rose 9% to $28.1M, led by soft-tissue products up 11%; bone-fusion sales declined 8%
  • Gross margin improved to 93% from 92%, but operating income fell to $1.8M as expenses increased 14% to $24.4M
  • Q2 continuing-operations loss reached $0.4M, or $0.05 per diluted share, versus $0.5M income previously
  • Six-month Adjusted EBITDA increased to $9.3M from $7.4M, while operating cash flow turned negative at $0.4M
  • Proposed MiMedx acquisition creates transaction-related upside but remains subject to shareholder, regulatory, and closing conditions

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Sanara MedTech Inc. 8-K filings

Get the next SMTI 8-K as it lands

Follow SMTI for push alerts, or ask the research agent what this filing means.